2,122 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Purchased by Virtus Advisers LLC

Virtus Advisers LLC acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,122 shares of the biotechnology company’s stock, valued at approximately $34,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 8.4% in the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock valued at $168,201,000 after purchasing an additional 1,018,273 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Arrowhead Pharmaceuticals by 138.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock worth $60,962,000 after purchasing an additional 2,774,933 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Arrowhead Pharmaceuticals by 1.0% during the 2nd quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock worth $47,067,000 after purchasing an additional 28,193 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Arrowhead Pharmaceuticals by 0.9% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 2,528,982 shares of the biotechnology company’s stock valued at $32,220,000 after buying an additional 21,686 shares in the last quarter. Finally, Norges Bank acquired a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at $30,414,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Insider Activity

In related news, Director Mauro Ferrari sold 8,750 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $56.39, for a total transaction of $493,412.50. Following the completion of the transaction, the director owned 68,764 shares of the company’s stock, valued at approximately $3,877,601.96. This represents a 11.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider James C. Hamilton sold 20,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the transaction, the insider directly owned 212,122 shares in the company, valued at approximately $7,424,270. This represents a 8.62% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 43,750 shares of company stock worth $1,643,413. Insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

ARWR has been the subject of several recent research reports. Morgan Stanley raised their price target on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Piper Sandler boosted their target price on shares of Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Royal Bank Of Canada raised their price target on shares of Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Finally, B. Riley upgraded shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.33.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $56.25 on Tuesday. The business’s 50-day moving average price is $39.63 and its 200 day moving average price is $26.34. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $59.15. The company has a market capitalization of $7.64 billion, a PE ratio of -43.95 and a beta of 1.27.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.